Gene Therapy Breakthrough for Maple Syrup Urine Disease (MSUD)

Sub : Sci

Sec: Health

Why in News

Scientists have developed a promising gene therapy for Maple Syrup Urine Disease (MSUD), a rare and severe genetic disorder.

What is Maple Syrup Urine Disease (MSUD)?

MSUD is a rare genetic metabolic disorder that affects the body’s ability to break down certain amino acids.
It results from mutations in three genes that encode the branched-chain alpha-keto acid dehydrogenase (BCKDH) complex.
BCKDH is a mitochondrial enzyme complex responsible for breaking down branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—into energy.
The inability to break down amino acids like leucine, isoleucine, and valine leads to the accumulation of toxic substances in the body.
The disease gets its name from the characteristic sweet-smelling urine of affected individuals.
Current Treatment Approaches:
- Strict Low-Protein Diet: Patients must avoid high-protein foods to prevent toxic amino acid buildup.
- Liver Transplantation: The most effective long-term treatment, but access to transplants remains limited.

How Does the New Gene Therapy Work?

The therapy utilizes an adeno-associated viral (AAV) vector to deliver functional copies of two key genes—BCKDHA and BCKDHB.
These genes restore the function of the BCKDH complex, enabling proper breakdown of amino acids.
The therapy was successfully tested in knockout cells and wild-type mice, demonstrating safety and efficacy.
Scientists identified a farm where calves were dying from classic MSUD. A single dose of the gene therapy carrying bovine BCKDHA and BCKDHB genes was administered to an affected calf.
Over two years, the treated calf grew normally and was able to consume a high-protein diet without complications.